As depicted in Figure 2B, PDE2A levels were notably lower in adrenocortical carcinoma (ACC), acute myeloid leukemia (LAML), lower-grade glioma (LGG), ovarian serous cystadenocarcinoma (OV), testicular germ cell tumors (TGCT), and uterine carcinosarcoma (UCS) tissues relative to their corresponding normal tissues. This evidence concerns the gene PDE2A and uterine carcinosarcoma.